CUPR Overview

Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.

Wall Street analysts forecast CUPR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CUPR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cuprina Holdings (Cayman) Ltd revenue for the last quarter amounts to -1.29 USD, decreased -79.39

Cuprina Holdings (Cayman) Ltd. EPS for the last quarter amounts to USD, decreased

Cuprina Holdings (Cayman) Ltd (CUPR) has 10 emplpoyees as of May 27 2026.

Today CUPR has the market capitalization of 5.79M USD.